Hutchmed
Clinical trials sponsored by Hutchmed, explained in plain language.
-
New pill shows promise for rare bleeding disorder in phase 3 trial
Disease control CompletedThis study tested a new drug called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants had failed at least one prior treatment. The goal was to see if the dr…
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 26, 2026 08:51 UTC
-
Healthy volunteers help check if new pill formula matches the original
Knowledge-focused CompletedThis study looked at two different versions of HMPL-523 acetate tablets to see if they are absorbed the same way in the body. Fifty-four healthy Chinese adults aged 18 to 45 took both versions at different times. The goal was to confirm the new formula works just like the origina…
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Knowledge-focused
Last updated May 26, 2026 08:33 UTC
-
Healthy volunteers test how meals change drug absorption
Knowledge-focused CompletedThis study looked at how eating a high-fat or low-fat meal changes the way the body absorbs HMPL-523 tablets. It involved 18 healthy adults who took the drug under different eating conditions. The goal was to gather information, not to treat any disease.
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Knowledge-focused
Last updated May 22, 2026 14:01 UTC